MedTrace Logo

A Study to Evaluate the Efficacy of Cytal® Burn Matrix in the Management of Partial-Thickness Burns to the Hand

NCT03598023 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-04-01

No results posted yet for this study

Summary

This is a randomized controlled trial (RCT) aimed at determining if use of Cytal® Burn Matrix in the management of partial-thickness burns to the hand shows improved wound healing times when compared to EZ-Derm Porcine Xenograft.

Conditions

  • Partial Thickness Burn of Hand

Interventions

DEVICE

Cytal® Burn Matrix

Cytal® Burn Matrix

DEVICE

EZ-Derm® Porcine Xenograft

EZ-Derm® Porcine Xenograft

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    collaborator OTHER

  • Integra LifeSciences Corporation

    lead INDUSTRY

Principal Investigators

  • Blair Summitt, MD · Vanderbilt University Medical Center, Regional Burn Center

  • Wesley Thayer, MD · Vanderbilt University Medical Center, Regional Burn Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2020-07-01
Completion
2020-12-31
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03598023 on ClinicalTrials.gov